Resistell enters clinical studies

Focusing on the problem of excessive time to results in Antimicrobial Susceptibility Testing (AST), Resistell developed a growth independent nanomotion diagnostic device that reduces the time to result from days to a few hours. This approach offers an alternative to culture-based antibiograms – the current gold standard in AST. Based on the detection of vibration caused by living bacteria, the rapid AST method enables patients with bloodstream infections and sepsis to receive the optimal medication sooner, saving lives and changing the future of diagnostics.

The startup has kicked off its Performance Evaluation Study (PES) at the Lausanne University Hospital (CHUV). HEMEX, one of the leading bench-to-market Life Science development firms in the Swiss ecosystem, is joining forces with Resistell to monitor the clinical trial over the next 12 months and bring it to successful completion. HEMEX has also supported Resistell with the design and submission of the clinical study. Having received approval from the Ethics Committee to conduct the study, the company is now a step closer to bringing its technology to market.

“HEMEX recognises the challenges early-stage startups face when entering the clinical development phase. As a CRO, HEMEX is proud to support startups like Resistell throughout their Performance Evaluation Study to help them bring great technology to the global market, improving diagnosis for patients. We are looking forward to the study starting as the hospital team prepares to collect some of the first patient samples. Monitoring the data entry and specific study objectives will help Resistell collect the clinical evidence needed. This will enable them to continue on their mission of making rapid AST diagnosis the new norm and reducing AMR”, said Pascal Winnen, CEO at HEMEX.

(Press release/RAN)